Combination therapy with amphotericin B and fluconazole against invasive candidiasis in neutropenic-mouse and infective-endocarditis rabbit models

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 6, 1997, Pages 1345-1348

  Sanati, Homayoon ^a,b   Ramos, Clarisa F ^a,b   Bayer, Arnold S ^a,b,c   Ghannoum, Mahmoud A ^a,b,c,d  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b St John's Cardiovascular Research Center   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIAL ENDOCARDITIS; CANDIDA ALBICANS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; MYCOSIS; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0030968679     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.6.1345     Document Type: Article

References (23)

1. Banerjee, S. N., T. G. Emori, D. H. Culver, R. P. Gaynes, W. R. Jarvis, T. Horan, J. E. Edwards, J. Tolson, T. Henderson, W. J. Marone, and the National Nosocomial Infections Surveillance System. 1991. Secular trends in nosocomial primary bloodstream infections in the United States - 1980-89. Am. J. Med. 91(Suppl. 3B):86S-90S.
2. Bayer, A. S., D. C. Norman, C. Y. Chiu, and C. C. Nast. 1989. Pathogenetic effects of neutropenia and steroid treatment in experimental pseudomonas endocarditis. Chemotherapy (Basel) 35:278-288.
3. Bolard, J., and J., Milhaud. 1996. Interaction of the anti-Candida amphotericin B (and other polyene antibiotics) with lipids, p. 253-274. In R. Prasad and M. A. Ghannoum (ed.), Lipids of pathogenic fungi. CRC Press Inc., Boca Raton, Fla.
4. Como, J. A., and W. E. Dismukes. 1994. Oral azole drugs as systemic antifungal therapy. N. Engl. J. Med. 330:263-272.
5. Gallis, H. A., R. H. Drew, and W. W. Pickard. 1990. Amphotericin B: 30 years of clinical experience. Rev. Infect. Dis. 12:308-329.
6. George, D., D. Kordick, P. Miniter, T. Patterson, and T. Andriole. 1993. Combination therapy in experimental invasive aspergillosis. J. Infect. Dis. 168:692-698.
7. Ghannoum, M. A., Y. Fu, A. S. Ibrahim, L. A. Mortara, M. C. Shafiq, J. E. Edwards, and R. S. Criddle. 1995. In vitro determination of optimal antifungal combinations against Cryptococcus neoformans and Candida albicans. Antimicrob. Agents Chemother. 39:2459-2465.
8. Hitchcock, C. (Pfizer Central Research, Sandwich, United Kingdom). Personal communication.
9. Humphrey, M. J., S. Jevons, and M. H. Tarbit. 1985. Pharmacokinetic evaluation of UK-49,858, a metabolically stable triazole antifungal drug, in animals and humans. Antimicrob. Agents Chemother. 28:648-653.
10. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeast. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
11. Odds, F. C. 1988. Candida and candidosis, 2nd ed., p. 96, 220, and 279-314. Bailliere Tindall, London, England.
12. Polak, A. 1989. Combination therapy for systemic mycosis. Infection 17:203-209.
13. Redding, S., J. Smith, G. Farinacci, M. Rinaldi, A. Fothergill, J. Rhine-Chalberg, and M. Pfaller. 1994. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility and DNA subtype analysis. Clin. Infect. Dis. 18:240-242.
14. Saag, M. S., and W. E. Dismukes. 1988. Azole antifungal agents: emphasis on new triazoles. Antimicrob. Agents Chemother. 32:1-8.
15. Sabra, R., and R. A. Branch. 1990. Amphotericin B nephrotoxicity. Drug Saf. 5:94-108.
16. Sanati, H., P. H. Belanger, R. A. Fratti, and M. A. Ghannoum. 1996. Effect of voriconazole (UK-109,496) on the sterol biosynthesis of Candida albicans and Candida krusei, abstr. C65. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
17. Sugar, A. M. 1986. The polyene macrolide antifungal drugs, p. 229-244. In P. K. Peterson and J. Verhoef (ed.), Antimicrobial agents, vol. 1. Elsevier Science Publishers, Amsterdam, The Netherlands.
18. Sugar, A. M. 1995. Use of amphotericin B with azole antifungal drugs: what are we doing? Antimicrob. Agents Chemother. 39:1907-1912.
19. Sugar, A. M., C. A. Hitchcock, P. F. Troke, and M. Picard. 1995. Combination therapy of murine invasive candidiasis with fluconazole and amphotericin B. Antimicrob. Agents Chemother. 39:598-601.
20. Tucker, R. M., P. L. Williams, E. G. Arathoon, B. E. Levine, A. I. Hartstein, L. H. Hanson, and D. A. Stevens. 1988. Pharmacokinetics of fluconazole in cerebrospinal fluid and serum in human coccidioidal meningitis. Antimicrob. Agents Chemother. 32:369-373.
21. Van 'T Wout, J. W., H. Mattie, and R. Van Furth. 1989. Comparison of the efficacies of amphotericin B, fluconazole, and itraconazole against a systemic Candida albicans infection in normal and neutropenic mice. Antimicrob. Agents Chemother. 33:147-151.
22. Witt, M. D., and A. S. Bayer. 1991. Comparison of fluconazole and amphotericin B for prevention and treatment of experimental Candida endocarditis. Antimicrob. Agents Chemother. 35:2481-2485.
23. Witt, M. D., T. Imhoff, C. Li, and A. S. Bayer. 1993. Comparison of fluconazole and amphotericin B for treatment of experimental Candida endocarditis caused by non-C. albicans strains. Antimicrob. Agents Chemother. 37:2030-2032.